Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Grifols, S.A.
  6. News
  7. Summary
    GRF   ES0171996087

GRIFOLS, S.A.

(GRF)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 01/20 05:44:57 am
16.93 EUR   +0.68%
01/19European ADRs Move Higher in Wednesday Trading
MT
01/18GRIFOLS S A : Egypt begins taking plasma donations
PU
01/11GRIFOLS S A : announces the expiration of the Asset sale Offer
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Grifols S A : launches new home-care treatment service for patients with alpha-1 antitrypsin deficiency in Spain

11/24/2021 | 05:20am EST

November 24, 2021

Grifols launches new home-care treatment service for patients with alpha-1 antitrypsin deficiency in Spain
Print this news Download the press release
  • The new service will include the administration of the intravenous treatments in patients' homes by a healthcare professional, avoiding a trip to the hospital
  • This offering is part of Grifols' AlfaCare, a comprehensive, personalized assistance program for patients with alpha-1 antitrypsin deficiency, including training, emotional support and tailored attention through specialized professionals
  • This pioneering program in Spain has more than 200 patients and now broadens its resources to include a nursing team skilled in home care

Barcelona, Spain, November 24, 2021 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, today announced a new home-infusion treatment service for patients with alpha-1 antitrypsin deficiency (AATD) in Spain.

This new service aims to increase treatment access and the comfort of its administration within Grifols' AlfaCare program. It offers an integrated, personalized program including training, emotional support and assistance to AATD patients through specialized professionals.

Grifols began AlfaCare in Spain three years ago, with the support of the Alpha-1 patient association in Spain. Since then it has demonstrated benefits in the promotion of self-care and the improvement in patients' quality of life.

The program, which already offers training with respiratory physiotherapists and emotional support from psychologists, now incorporates administration of the intravenous treatment at home, which will eliminate travel time and waiting in hospitals. The first patients are already benefiting from the service and it is expected that others will enroll in the upcoming months.

AATD is a rare genetic disease defined by a deficiency or absence of the alpha-1 antitrypsin protein in the blood. It is the most common cause of severe pulmonary emphysema and chronic obstructive pulmonary disease (COPD) in adults, in addition to being the most common cause of liver disease in children. AATD symptoms vary depending on the degree of severity and type of genetic mutation, as well as on external factors. It is estimated that AATD affects 3.4 million people around the world1 and 14,500 in Spain2.

"AlfaCare is part of Grifols' commitment to improve quality of patients' lives," said Joana Sabat, vice president Global Marketing, Bioscience Division. "In collaboration with patient associations, we will improve the knowledge and diagnosis of diseases such as alpha-1 antitrypsin deficiency. It is critical to recognize its prevalence, and know how to diagnose it and treat it."

Grifols' commitment to caring for AATD patients through the educational support program and at-home therapy administration complements the company's research activity in the field, which is focused on developing new early diagnosis tests and new approaches to treating the disease.

Grifols has similar support programs for patients with AATD in other countries such as Italy, Canada and the United States.

About AATD

AATD is a rare hereditary disease defined by a deficiency or absence of the alpha-1 antitrypsin protein in plasma. It is the most common cause of severe pulmonary emphysema and chronic obstructive pulmonary disease (COPD) in adults, as well as the most common cause of liver disease in children.

This illness is more prevalent than other rare lung diseases such as cystic fibrosis and pulmonary arterial hypertension. AATD symptoms vary depending on the degree of severity and type of genetic mutation, as well as external factors.

AATD affects some 3.4 million people around the world, although most do not know they have it. In Spain, it is estimated that about 14,500 people have the disease.

For more information about alpha-1 antitrypsin deficiency, please visit:www.alpha1.org.

1de Serres F. J. (2003). Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environmental health perspectives, 111(16), 1851-1854. <
2Blanco, I., Bueno, P., Diego, I., Pérez-Holanda, S., Casas-Maldonado, F., Esquinas, C., y Miravitlles, M. (2017). Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. International journal of chronic obstructive pulmonary disease, 12, 561-569.

Disclaimer

Grifols SA published this content on 24 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2021 10:19:04 UTC.


ę Publicnow 2021
All news about GRIFOLS, S.A.
01/19European ADRs Move Higher in Wednesday Trading
MT
01/18GRIFOLS S A : Egypt begins taking plasma donations
PU
01/11GRIFOLS S A : announces the expiration of the Asset sale Offer
PU
01/11Tender Offer - Results Announcement
AQ
01/10European ADRs Move Lower in Monday Trading
MT
01/04European ADRs Move Higher in Tuesday Trading
MT
2021European ADRs Modestly Lower Tuesday
MT
2021GRIFOLS S A : moves forward with its divestment plan by agreeing to sell VCN Biosciences
PU
2021GRIFOLS S A : December 14, 2021Grifols moves forward with its divestment plan by agreeing ..
PU
2021GRIFOLS S A : announces the commencement of an Asset sale Offer
PU
More news
Analyst Recommendations on GRIFOLS, S.A.
More recommendations
Financials
Sales 2021 5 272 M 5 982 M 5 982 M
Net income 2021 529 M 600 M 600 M
Net Debt 2021 6 138 M 6 966 M 6 966 M
P/E ratio 2021 22,0x
Yield 2021 1,58%
Capitalization 9 978 M 11 324 M 11 323 M
EV / Sales 2021 3,06x
EV / Sales 2022 2,82x
Nbr of Employees 23 431
Free-Float 79,7%
Chart GRIFOLS, S.A.
Duration : Period :
Grifols, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRIFOLS, S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 16,82 €
Average target price 25,52 €
Spread / Average Target 51,7%
EPS Revisions
Managers and Directors
Raimon Grifols Roura Joint Chief Executive Officer & Executive Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
VÝctor Grifols Roura Non-Executive Chairman
Xavier Sueiras Gil Chief Information Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
GRIFOLS, S.A.-0.36%11 324
CSL LIMITED-6.99%93 475
WUXI BIOLOGICS (CAYMAN) INC.-6.16%46 973
SAMSUNG BIOLOGICS CO.,LTD.-9.63%45 408
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-3.80%33 904